Social Capital Hedosophia Holdings Corp. (“IPOA”), which raised $690 million on September 13th, 2017, nearly one year ago today, might be in trouble.
According to Axios and the Silicon Valley Business Journal, the venture firm of Chamath Palihapitiya, who is IPOA’s Chairman and CEO, is “imploding“. Failed venture firms are not totally shocking, but both articles pointedly place the blame squarely on Mr. Palihapitiya.
From the Silicon Valley Business Journal:
“Social Capital appears to be done, at least as a major venture capital investor,” Primack writes.
The firm’s leadership team is “hemorrhaging” its top talent, its limited partners are deeply unhappy with the ways things are being run, and its hedge fund is shutting down, Primack reports.
In addition, “Palihapitiya is regularly absent from the Social Capital offices, instead spending much of his time in Europe. He also is said by multiple sources to have repeatedly blown off investor meetings, sometimes sending regrets just minutes before they were to begin,” according to the report.
Current and former Social Capital employees say it could take days or weeks to get email replies from Palihapitiya.
In a tweet on Friday afternoon, Palihapitiya said the Axios story was “not accurate,” but did not elaborate further.
Social Capital Hedosohia still has one year of life left until they need to complete, but that detail is cold comfort to investors. The share is currently trading at $9.87, but the warrant is trading down nearly 10% at $1.22.
Having said that, a lot can happen in twelve months. And if you REALLY want to try and find a silver lining in all this, maybe if the venture firm shuts down it will force Mr. Palihapitiya to focus full-time on the SPAC.
Everybody loves a comeback.
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...
At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...
AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...
Trump Media (NASDAQ:DJT) is down about -15% in the pre-market following the filing of its first S-1 since closing its combination with Digital World, and this includes the issuance of the 21,491,251 shares. Of these, 14,375,000 are to be made available for those exercising warrants while the rest would go out to note holders from...
At the SPAC of Dawn This week, bookended by the end of Ramadan and the beginning of Passover, could wind up stacked with events to avoid those holiday times, but for now SPACs have scheduled just six extension votes for this stretch. Redwood (NASDAQ:RWOD) and Genesis Growth Tech (OTC:GGAAF) have yet to release results from...